Sangamo Therapeutics, Inc.
SGMO
$0.44
-$0.01-1.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -37.13% | 565.52% | 239.92% | -67.20% | -74.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.13% | 565.52% | 239.92% | -67.20% | -74.04% |
| Cost of Revenue | -25.26% | -38.55% | -50.56% | -51.61% | -43.53% |
| Gross Profit | 18.08% | 86.14% | 80.11% | 0.93% | -95.13% |
| SG&A Expenses | -23.23% | -28.94% | -20.07% | -25.70% | -24.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.74% | -36.25% | -44.18% | -46.25% | -39.55% |
| Operating Income | 19.92% | 71.60% | 66.57% | 13.95% | -25.00% |
| Income Before Tax | 18.91% | 74.45% | 76.11% | 62.68% | 46.92% |
| Income Tax Expenses | -3,583.33% | -116.50% | 97.17% | 96.71% | 99.74% |
| Earnings from Continuing Operations | 19.23% | 74.64% | 75.78% | 62.01% | 45.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.23% | 74.64% | 75.78% | 62.01% | 45.96% |
| EBIT | 19.92% | 71.60% | 66.57% | 13.95% | -25.00% |
| EBITDA | 19.67% | 72.43% | 66.73% | 6.03% | -41.51% |
| EPS Basic | 39.96% | 79.35% | 79.75% | 65.09% | 48.60% |
| Normalized Basic EPS | 37.63% | 75.96% | 71.37% | 14.46% | -31.77% |
| EPS Diluted | 39.74% | 78.68% | 79.25% | 64.61% | 48.67% |
| Normalized Diluted EPS | 37.78% | 75.80% | 71.23% | 14.41% | -31.67% |
| Average Basic Shares Outstanding | 28.75% | 21.20% | 18.79% | 15.07% | 12.49% |
| Average Diluted Shares Outstanding | 27.75% | 22.01% | 19.63% | 15.82% | 13.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |